Category Archives: Psychedelics

NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, is highlighting the latest CEO comments and news from companies recently presenting at its highly acclaimed NEXT SUPER STOCK livestream investor conferences, and investor LiveChats on social media streams. Over 160,000 investors have participated in Wall Street Reporters livestream events in the past 30 days.

Interactive Games Technologies (CSE: BETS) (OTC: BLITF), CEO Chris Neville: "Building Next Billion Dollar Global Betting Giant"

In a recent interview at Wall Street Reporters NEXT SUPER STOCK livestream, Interactive Games Technologies (OTC: BLITF) (CSE: BETS) CEO Chris Neville, shares his companys ambitious global strategy, with a unique focus on India. As a pioneer of online gaming with almost 20 year's experience, Neville sees a strong parallel between the poker boom of the early 2000s and the Indian market today.

Watch (CSE: BETS) (OTC: BLITF) NEXT SUPER STOCK Video: http://bit.ly/2Zuubon

India is one of the fastest growing online gaming markets in the world. With a growing population, especially the middle class, a burgeoning economy, the fastest internet adoption in the world, and with 65% of the population under the age of 35, India is the perfect storm for skill based online gaming.

Interactive Games Technologies (OTC: BLITF) (CSE: BETS) sees India as the perfect launchpad for its global betting business, with relatively low customer acquisition costs, less competition, and blue sky upside potential. By partnering with Indian social influencers such Bollywood celebrities and cricket stars, BLITF reaches their 150 million followers in India. BLITF is also expanding into new untapped global gaming markets such Canada which is about to legalize sports betting.

March 23 - BLITF reports that launch of its recently acquired skill-based fantasy gaming product, BLITZPOOLS, is exceeding expectations. BLITZPOOLS is already over 150,000 new registrations and expects to close the month with over 250,000 new players. It is clear the industry leading product and brand positioning is resonating with the Indian fantasy gaming audience, and is now one of Indias fastest-growing skill-based fantasy sports platforms.

Story continues

March 16 - BLITF announces plans to enter US gaming market. BLITF management is in talks with US land-based casino to partner in building and managing a digital gambling platform and offering. Morgan Stanley estimates that the U.S. online gambling market (sports betting and iGaming) will soon top $20 billion Gross Gaming Revenue per year. The lack of permissive online gambling regulations until recently in the U.S. means that online gambling experience is limited in the U.S. market. Online gambling has, however, been permitted in other countries and regions for over two decades. BLITF has assembled a team of online gambling executives, with over 100 years online gambling experience, and believes can provide land-based operators with the knowledge, experience and expertise to capitalise on the growing US online gambling market. BLITF CEO, Chris Neville said: The Company is hugely excited by this opportunity in the burgeoning U.S. online gambling market. We have a great team and a great partner to add significant value to future potential partners in this space.

March 8 - BLITF announces signing of rising cricket stars Ishan Kishan, Rahul Chahar, Shreyas Gopal and Wriddhiman Saha to be the face of the brand. Attracting their ever-growing and large fan base to the app, the cricketer quartet will be an integral part of the 360-degree digital and offline campaign activation of BLITZPOOLS. In addition to these cricket stars and as part of the new brand launch, BLITZPOOLS has engaged celebrities and influencers alike with a total follower count in excess of 215 million, the identities of which will be revealed at time of post and in a future release.

Watch (CSE: BETS) (OTC: BLITF) NEXT SUPER STOCK Video: http://bit.ly/2Zuubon

Hapbee Technologies (OTC: HAPBF) CEO Scott Donnell: Tech That Lets You Choose How you Feel = Billion Dollar Market OpportunityOne of the most unique companies to present at Wall Street Reporters NEXT SUPER STOCK livestream events in recent years, is Hapbee Technologies (OTC: HAPBF) which markets wearable tech that lets you choose feelings on demand. The patented technology uses low-power electromagnetic signals designed to produce sensations such as Happy, Alert, Focus, Relax, Calm and Sleepy. HAPBF is developing new feeling signals regularly which are available on a subscription basis through its mobile app.

In his interview with Wall Street Reporter, Hapbee CEO Scott Donnell explains how Hapbees technology platform addresses untapped multi-billion dollar market opportunities which include mental health, sleep, and fitness, among other aspects of our daily lives which are impacted by feelings. Scott also shares HAPBFs unique D2C e-commerce strategy which is based on proven systems of todays most successful billion-dollar D2C fitness, health and lifestyle brands. Hapbee is rapidly being embraced by influencers in fitness/wellness, biohackers, and high-performance executives who want to perform and feel their best. HAPBF unique technology positions it at the forefront of the fast growing $32 billion wearable tech market.

Watch Hapbee Technologies (OTC: HAPBF) NEXT SUPER STOCK Video: http://bit.ly/3vh6Ncx

ESE Entertainment (TSX.V: ESE) (OTC: ENTEF) CEO Konrad Wasiela: E-Sports M&A Pipeline With Over $100 million Annual Revenues

ESE Entertainment (TSX.V: ESE) (OTC: ENTEF) CEO Konrad Wasiela, a featured presenter at Wall Street Reporters NEXT SUPER STOCK investors livestream conference, recently updated investors on his goal of building ESE into a billions dollar global enterprise. Wasiela shared that ESE now has a growing M&A pipeline with over $100 million annual revenues and expected to close a significant number of these potential transactions in the coming months. ESEs stated goal is to build a global E-Sports business with a valuation of $1 Billion+.

Watch ESE (OTC: ENTEF) Next Super Stock livestream video: https://bit.ly/3qq59mb

In his interview with Wall Street Reporter, ESE CEO Konrad Wasiela, says the company is now ready to scale - expanding its global footprint, with new partnerships with global brands like Porsche, driving revenue growth with aggressive focus on top line sales and margin expansion, and M&A opportunities. ESE is now rapidly expanding, with multiple revenue streams including, E-Sports infrastructure software powering global tournaments, exclusive digital media distribution, broadcast rights, and owning world-class leagues and teams, including its K1CK global E-Sports franchise.

March 17 - ENTEF announces launch of Virtual Pitstop, a new business unit dedicated to simulation racing (sim racing). Virtual Pitstop will provide technology for video game developers, racing fans, and gamers to engage in motorsport related esports across the globe. ENTEF CEO Konrad Wasiela, commented, We are excited to announce the expansion of our digital Motorsport business with the launch of the Virtual Pitstop brand. Our past successful partnerships and business collaborations with Porsche, Kia, and Orlen are just the beginning. We see a significant opportunity to implement fast growing technology and monetization via AR/VR, NFTs, skins, and more.

Watch ESE (OTC: ENTEF) Next Super Stock livestream video: https://bit.ly/3qq59mb

Delic Holding (CSE: DELC) (OTC: DELCF) CEO Matt Stang: Psychedelics For Mental Health Is Major Growth Trend

In a recent interview at Wall Street Reporters Investors Discovery Day livestream, Delic Holdings (OTC: DELCF) CEO Matt Stang shared his unique strategy for capitalizing on what is expected to be the next massive new market opportunity: psychedelics. As the former publisher of High Times Magazine over 14 years, Matt Stang paved the way for cannabis legalization, and along the way, developed a network of industry pioneers who are now active in the psychedelics space. In his interview, Stang explains DELCFs unique psychedelics ecosystem business model - which offers synergies, and leverage - and generates revenues across the entire psychedelics value chain.

DELCFs ecosystem spans across an online media platform which provides consumers information and reviews, on psychedelics - an expanding chain of ketamine treatment clinics - to a licensed research lab developing innovative psychedelics product formulations - to clinical research data for biotech & pharma for developing new psychedelic compounds. DELCF intends to expand this ecosystem further, through M&A, leveraging Matt Stangs 14 years of experience and wide industry contacts across the industry.

Watch DELCF NEXT SUPER STOCK video: http://bit.ly/3uK4L4y

March 5 - DELCF announces acquisition of the Homestead brand and intellectual property. Homestead is a legacy counterculture distributor of psychedelic media and creator of one of the first self-contained mushroom grow kits. Matt Stang, Founder and CEO of DELCF commented, "The acquisition of Homestead is an exciting one for us at DELIC. It shows how we are increasing accessibility to this nascent industry within regulated jurisdictions. Homestead not only sold tens of thousands of mushroom kits globally but also was one of the earliest distributors for High Times and many other counter culture publications. We look forward to growing together and increasing shareholder value with what we accomplish."

February 25 - DELCF announces acquisition of Complex Biotech Discovery Ventures, a licensed psilocybin and cannabis research laboratory focused on extraction, analytical testing, and chemical process development. Founded by award-winning chemist, Dr. Markus Roggen, and UBC Professor, Glenn Sammis, CBDV supports the psychedelic industry with high precision chemical analytics and metabolomic identification.

Watch DELCF NEXT SUPER STOCK video: http://bit.ly/3uK4L4y

WALL STREET REPORTER

Wall Street Reporter (Est. 1843) is the leading financial news provider, focused on giving investors direct access to CEO's of promising, publicly-traded companies, and market experts. http://www.WallStreetReporter.com. Nothing in this news summary shall be construed as investment advice. Quotes/content may be edited for brevity and context. Full disclaimer, and relevant SEC 17B disclosures here: http://bit.ly/39kkE7K

About Wall Street Reporters Next Super Stock conference:

Wall Street Reporter's NEXT SUPER STOCK Live! conference is dedicated to featuring select companies that have near-term catalysts in place which can drive transformational growth (and stock appreciation) in the months ahead. Click here to join next livestream event: https://www.wallstreetreporter.com/next-superstock-online-investor-conference/

CONTACT:

WALL STREET REPORTER

(212) 871-2057 ext 7

http://www.WallStreetReporter.com

Here is the original post:

NEXT SUPER STOCKS On The Move: E-Sports, Psychedelics, iGaming, and FeelTech - CEOs of BLITF, ENTEF, HAPBF and DELCF, Positioning for Explosive...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (Cybin or the Company), a biotechnology company focused on progressing psychedelic therapeutics, today announced key senior management changes to lead the buildout of its development and clinical operations in the United States and Europe. Effective immediately, Alexander Belser, PhD, will serve as Chief Clinical Officer, and Aaron Bartlone will serve as Chief Operating Officer of Cybin US Holdings Inc. The Company also announced that co-founder and former Chief Operating Officer, Paul Glavine will assume the role of Chief Growth Officer of Cybin Inc., and co-founder and former SVP, Business Development, John Kanakis will assume the role of Chief Business Officer.

We are committed to building our presence both in the United States and in Europe to advance our mission of improving mental healthcare through therapeutic development programs and innovative drug delivery systems. These appointments will serve to strengthen our development and clinical operations globally and solidify Cybins position within the industry. Alex and Aaron bring deep clinical, commercial and regulatory expertise that will serve to broaden our management and scientific leadership teams. We look forward to their contributions as we pursue increased visibility across these additional markets, stated Doug Drysdale, Chief Executive Officer.

Paul and Johns extensive entrepreneurial experience was instrumental in shaping the initial formation of Cybin and the companys subsequent emergence as a leader within the psychedelics space. Their deep commitment to Cybins mission will continue as they assume these new roles and will allow them to further accelerate business development and investor awareness initiatives. We believe these appointments are an important step in taking Cybin to the next level, concluded Drysdale.

Mr. Bartlone is an accomplished biopharmaceutical executive with a proven track record across numerous therapeutic and functional areas, including quality assurance, regulatory affairs, product development, compliance, and commercial operations. Prior to joining Cybin, Mr. Bartlone was President & Managing Director at AB Dynamix LLC, where he was responsible for developing customized and innovative quality management systems, regulatory strategies, and supply chains for developing pharmaceutical, biotechnology, and medical device companies. Previously, Mr. Bartlone held positions of increasing responsibility at UCB Inc., a global pharmaceutical company, including Commercial President and Chief Quality, Patient Safety, Health Safety & Environment & Risk Officer. Mr. Bartlone has developed global teams of over 1,000 colleagues in 50 countries and has successfully driven over 25 small and large molecular therapies and drug-device combination products to the global marketplace. Mr. Bartlone has also held various director-level research, quality, regulatory, and managerial positions at Eli Lilly. Mr. Bartlone has a Bachelor of Science in Chemistry from Youngstown State University and a Master of Science in Analytical Chemistry from the University of Notre Dame.

Dr. Alexander Belser is a well-known leader in the field of psychedelic research, having served as an investigator on clinical trials of psilocybin and MDMA to treat depression, anxiety, substance use, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and end-of-life distress at New York University and Yale University. Dr. Belser previously served as Chief Clinical Officer at Adelia Therapeutics, where he directed the clinical program investigating tryptamines and phenethylamines for a variety of treatment indications. Dr. Belser is the founding President of Nautilus Sanctuary, the first non-profit center for psychedelic medicine in the eastern United States. Dr. Belser has taught widely on the topic of psychedelic medicine, having authored a dozen peer-reviewed publications and given over fifty lectures, presentations, and Grand Rounds on psychedelic topics. As a Clinical Research Fellow and Co-Investigator at Yale University, Dr. Belser investigated psychedelic treatments for major depression and for OCD. Dr. Belser has worked as a therapist on studies of MDMA-assisted psychotherapy for the treatment of severe PTSD. Dr. Belser trained at Bellevue Hospital, Mount Sinai Beth Israel Hospital, and New York Psychiatric Institute at Columbia University. Dr. Belser has also received extensive training in psychedelic psychotherapy from recognized senior teachers. Dr. Belser has Bachelor of Arts degrees in English and Government from Georgetown University, a Master of Arts in Philosophy from Cambridge University, and a PhD in Counseling Psychology from New York University.

About Cybin

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

Cautionary Notes and Forward-Looking Statements

Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as may, should, could, intend, estimate, plan, anticipate, expect, believe or continue, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the development of the Companys operations and presence in the United States and Europe and the Companys advancement of therapeutic development programs and innovative drug delivery systems. There are numerous risks and uncertainties that could cause actual results and Cybins plans and objectives to differ materially from those expressed in the forward-looking information. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

Cybin makes no medical, treatment or health benefit claims about Cybins proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybins performance and operations.

The NEO Exchange has neither approved nor disapproved the contents of this news release and is not responsible for the adequacy and accuracy of the contents herein.

See the rest here:

Cybin Announces Senior Management Changes to Lead Buildout of Development and Clinical Capabilities in the United States and Europe - Business Wire

Wikipedia list article

The following is a list of psychedelic drugs of various chemical classes, including both naturally occurring and synthetic compounds. Serotonergic psychedelics are usually considered the "classical" psychedelics[dubious discuss], whereas the other classes are often seen as having only secondary psychedelic properties; nonetheless all of the compounds listed here are considered psychoactive and hallucinogenic in humans to some degree.

Some of these compounds may be classified differently or under more than one category due to a unique structural classification, multiple mechanisms of action, or the fact that the precise pharmacodynamic actions of the compound are not yet completely understood. Because of the vast amount of possible substitutions and chemical analogs of most psychedelic compounds, the total diversity of chemical compounds which produce psychedelic effects in humans is not fully reflected within this list, leaving room for many that have not yet been sufficiently investigated and others that have not yet been discovered.

Naturally occurring compounds are marked with a .

Link:

List of psychedelic drugs - Wikipedia

Timothy Learys dead.

The Moody Blues, 1968

Psychedelics derived from plants have been used in religious ceremonies for centuries, and in 1938, the first synthetic psychedelic, lysergic acid diethylamide (LSD), was synthesised by the Swiss chemist Albert Hoffman. By 1947, LSD was marketed as a psychotherapy medication, and in 1960, Harvard psychologist Timothy Leary began popularising LSD and psilocybin, the hallucinogenic compound in magic mushrooms, as mind-altering therapeutics. However, by the mid-1960s, amidst growing concerns in the U.S. and Europe about the illicit production of LSD and its growing use for recreational purposes in the absence of medical supervision, the U.S. Congress passed the Drug Abuse Control Amendments, making it a misdemeanour to manufacture or sell LSD without a license. By 1970, psychedelic research was largely halted by the passage of the Controlled Substances Act of the Comprehensive Drug Abuse Prevention and Control Act in the U.S. and similar legislation in Europe. Timothy Learys vision for psychedelics indeed seemed dead, as foretold by Ray Thomas of the Moody Blues.

However, over the past decade, a resurgence of clinical research has shifted perceptions that psychedelics are neurotoxic substances to potential therapeutics for psychiatric disorders. Globally, psychiatric disorders are a major public health problem, affecting approximately 350 million people, many of whom do not respond to conventional treatment. Recent clinical evidence suggests psychedelics can help these patients.

Psychedelics are chemicals that alter ones perception of reality by modulating how nerve cells in the brain communicate with each other. In addition to LSD and psilocybin, psychedelics include ketamine, 3,4-methylenedioxymethamphetamine, also known as MDMA or ecstasy, and phytocannabinoids, the psychoactive chemicals in marijuana. The U.S. Drug Enforcement Agency (DEA) classifies these drugs according to their potential for abuse: LSD, psilocybin, MDMA, and delta-9-tetrahydrocannabinol (9-THC), a psychoactive phytocannabinoid in marijuana, are classified as schedule I controlled substances with no currently accepted medical use and a high potential for abuse. Ketamine is classified as a schedule III controlled substance with moderate to low potential for physical and psychological dependence.

These drugs can also be classified according to their psychoactive effects. LSD, psilocybin and MDMA are hallucinogens. MDMA also has stimulant properties, meaning it can elevate mood and increase alertness and energy. Simulants are often highly addictive and can cause paranoia over time. Ketamine is a dissociative anaesthetic, defined as distorting sensory perceptions and causing feelings of disconnection or detachment. Counterintuitively, at lower doses, ketamine can act as an empathogen, promoting feelings of sympathy and empathy. 9-THC in marijuana has hallucinogenic, stimulant and depressive actions.

Chronic use or high-dose acute exposure to psychedelics can be neurotoxic, causing addiction, paranoia, panic attacks, high blood pressure and, in severe cases, loss of consciousness and seizures. Both human and animal studies demonstrate that toxic exposures to psychdelic drugs can change the structure and function of the brain, possibly by causing excessive or overstimulation, oxidative stress or neuroinflammation. The developing brain is especially vulnerable to the neurotoxic effects of these drugs, because they can disrupt the normal pattern of connections made between brain cells during brain development. Children exposed to psychedelic drugs during pregnancy or breast-feeding have an increased risk of developing psychiatric disorders.

Recent clinical studies suggest that psilocybin, MDMA, ketamine and phytocannabinoids can reduce depression and anxiety in patients who do not response to conventional treatment. MDMA and psilocybin have been designated by the U.S. Food and Drug Administration as breakthrough therapies for posttraumatic stress disorder (PTSD) and treatment-resistant depression, respectively. MDMA shows promise as a treatment for social anxiety in autistic adults and psilocybin, for cancer-related anxiety. A single, subanesthetic dose of ketamine in addition to psychotherapy can rapidly improve symptoms in patients with a major depressive disorder for up to 7 days. While preliminary, research supports the use of LSD in the treatment of psychiatric disorders. Clinical data suggest psychedelic drugs may also be effective in treating substance abuse disorders, end-of-life psychiatric distress, and suicide ideation. Marijuana, and in particular the phytocannabinoid cannabidiol (CBD), can reduce pain and relieve anxiety. In addition CBD has been approved for treatment-resistant seizure disorders.

It is not clear yet how psychedelics work as therapeutics, but emerging data suggests these drugs protect against atrophy of neurons and promote outgrowth of neurites, the processes extended by neurons that determine how neurons connect with each other. Notably, neurites are diminished in many treatment-resistant psychiatric disorders. Psychedelic drugs are not being used as stand-alone drug treatments, but rather they are used on one or a few occasions during psychotherapy sessions to overcome obstacles to successful psychotherapy and to boost the therapeutic experience. It is theorised that the experience itself, rather than simply the pharmacological effects of the drug, leads to cure or sustained remission of severe, treatment-resistant psychiatric disorders.

Due in part to clinical studies documenting the therapeutic potential of psychedelics, 37 states in the U.S. have legalised the use of medical cannabis and cities in Colorado, California, and Massachusetts have decriminalised psilocybin. Oregons Measure 110 decriminalised the possession of small amounts of psychedelic drugs and increased access for medical uses. While the regulation and perception of psychedelics is changing, this should not be interpreted as meaning these drugs are considered safe. Indeed, the Sacramento County District Attorneys Laboratory of Forensic Services reports cannabis and stimulants are among the most commonly reported substances of abuse in cases of driving under the influence of drugs (DUID) and drug seizures. Additional safety studies to determine the long-term effects of the therapeutic use of psychedelics are needed to support their clinical use. These limitations notwithstanding, the preliminary clinical data on the therapeutic potential of psychedelic drugs warrant further research, with particular focus on synthesising derivatives of these compounds that retain therapeutic effects while eliminating addictive and neurotoxic effects.

Please note: This is a commercial profile

Editor's Recommended Articles

More:

The changing perspective of psychedelic drugs with a history of abuse - Open Access Government

As psychedelics gain ground as a potential therapy for mental health disorders, there remains a pressing concern that patients in clinical trials may have adverse effects to the drugs.

New research identifies personality traits that have been associated with positive and negative experiences on psychedelics in previous studies, information that could help predict how future clinical trial participants will respond to the drugs.

The findings suggest that people more open to new experiences and willing to surrender to the unknown may be best positioned to have a positive experience on psychedelics, and individuals who tend to be preoccupied or apprehensive could be more likely to have a negative, or challenging, experience.

These predictions could be used by scientists to help hesitant clinical trial patients feel more open to the potential therapy, possibly by offering lower doses as a starting point, researchers say though such a concept remains speculative.

The findings point to interesting testable things we can look at in future research, saidAlan Davis, assistant professor ofsocial work at The Ohio State University and senior author of the review. It might be plausible to use threshold doses that are smaller than those used in a trial as a first exposure so people have less anxiety, experience the benefit and, from that, go into a higher dose later.

The study is published online in the journal ACS Pharmacology & Translational Science.

To arrive at these predictions, the researchers reviewed 14 published clinical trials and other types of studies conducted in recent years that documented participants personality traits or states of mind and their associations with a positive or negative experience on psychedelics.

Its been an open question so far in psychedelic science: How can we predict how people will react? We thought this review would be a good opportunity to develop a narrative of what the consensus is so far, said study first author Jacob Aday, a PhD candidate in psychology at Central Michigan University who collaborates with Davis.

Preliminary evidence has suggested that psychedelics may be effective in treating mood, anxiety, trauma-based and substance use disorders.

Psychedelics might broadly apply to a whole range of different psychiatric problems, and in part that might be because theyre directly affecting neurotransmission and the brains ability to communicate in new ways that involve different parts of the brain, Davis said. But there is still a lot to unpack about exactly how this all works and why it may be effective.

Of the studies reviewed, 10 tested psilocybin (commonly known as magic mushrooms) as a therapy, two involved LSD, one used a hallucinogenic brew called ayahuasca and one examined psychedelic use in general.

Experiences on psychedelics vary in intensity and tend to comprise three categories: a mystical, insightful or challenging experience. A mystical experience can feel like a spiritual connection to the divine, an insightful experience increases peoples awareness and understanding about themselves, and a challenging experience relates to emotional and physical reactions such as anxiety or increased arousal.

The review suggests that people who are high in the traits of openness, acceptance and absorption the tendency to immerse oneself into imaginative experiences and in a psychological state of surrendering to whatever may transpire are more likely to have positive psychedelic experiences.

A state of surrender, in particular, stood out for its association with a lower chance for acute dread and a higher likelihood of a mystical experience and what is known as ego dissolution, when ones sense of self gives way to a closer connection to other people and the broader world.

In contrast, people who are low in those traits or who are in preoccupied, apprehensive or confused states are considered more likely to experience adverse reactions.

There was also tentative evidence that increased experience with psychedelics and increased age were associated with slightly less intense effects with the drugs, Aday said. And there werent any differences according to sex. Men and women responded similarly.

Three studies had identified potential neurological markers that could help predict research participant reactions to psychedelics, but the cost of collecting brain scans to screen trial candidates made them less practical predictors than psychological traits, Aday said.

Davis has already considered potential reactions to psychedelics for a psilocybin trial he is planning for veterans who have post-traumatic stress disorder.

People who have experienced trauma are not very high in surrender, because they are anxious all the time about their past traumatic experiences, he said. A possibility to explore is starting with a low or moderate dose prior to giving the full therapeutic dose, which might help them increase in surrender. Weve designed the study this way, thinking that might be helpful.

Study co-authors include Cayla Mitzkovitz, Emily Bloesch and Christopher Davoli of Central Michigan University.

Here is the original post:

Predicting who may do best with psychedelic-assisted therapy - The Ohio State University News

Among the leading contenders in the race to pioneer new blockbuster psychiatric drugs is Vancouver-headquarteredXPhyto Therapeutics Corp.This small opportunity-driven life sciences accelerator that operates a range of R&D projects in both Canada and Germany.

They include XPhytos new psychedelics division called XPhyto Laboratories. The companys near-term focus entails the formulation of psychedelic compounds such aspsilocybin derived from various psychoactive mushrooms and mescaline derived from peyote and other cactus species into mood-improving and therapeutic pharmaceutical drugs.

In particular, its expertise in using sublingual and transdermal therapeutics to deliverprecise dosing of very dose-specific drugs, like fentanyl, will prove invaluable in this opportunity-driven undertaking.

XPhytos psychedelic research is led by Professor Raimar Lbenberg. Although he developed his professional expertise in Germany, he is nowone of the few medical scientists working in North America who has the necessary government-level clearance to develop experimental pharmaceutical psychedelic drugs in a leading university laboratory.

LbenbergsHealth Canada licences for research and analytical testing allow him to work with LSD,psilocybin, MDMA, and other psychotropic molecules.

Professor Lbenberg explains: Our initial focus is to develop standardised drug formulations with precise, predictable, and efficient delivery of their active pharmaceutical ingredients for clinical study and therapeutic use. We see a lot of potential therapeutic value in psychedelic compounds for their ability to positively influence neural networks through growth and reorganisation.

As a founder and director of the Drug Development and Innovation Centre at the University of Alberta and the former president of the Canadian Society for Pharmaceutical Sciences, ProfessorLbenbergis a hard-nosed scientist with many years of expertise in pharmacology.

In addition to DrLbenbergs laboratory, team, and drug development expertise,one of the companys German subsidiaries Vektor Pharma TF GmbH has globally recognised drug delivery technology and manufacturing capabilities. Vektor specialises in the use of proprietary oral/transmucosal strips to optimise the uptake of orally administered drugs.

It is well worth noting that most drugs that are delivered via this method are shown to have especially high bioavailability. They also provide a faster onset and more predictable level of efficacy because the drug does not need to be metabolised via the liver. Dosage-control will be vital to the judicious administration of such powerfully potent drugs as psychedelics, ProfessorLbenberg adds.

XPhyto intends to first produce psychedelic active pharmaceutical ingredients, which can then be incorporated into our novel sublingual and transdermal delivery systems. This is our competitive advantage, from production of API to drug formulation to clinical validation, he said.

In this regard, XPhyto is doing pre-clinical laboratory work with a focus on the following psychotropic compounds: psilocybin, mescaline, LSD, MDMA, and DMT.

All of these mind-expanding compounds are known to modulate neurotransmitters such as serotonin and dopamine, which regulatecognition, perception, and mood. This makes them well suited to treating a variety of mental conditions, which also include post-traumatic stress disorder (PTSD), according to several early-stage clinical trials.

There have been few meaningful advances in the development of psychiatric drugs since the late 1980s. This was whenselective serotonin reuptake inhibitors (SSRIs) the healthcare industrys go-to antidepressant of choice were first commercialised.

Yet antidepressants fail to help up to 30% of those prescribed. And they can be highly addictive among people who do find them therapeutic.So, according to many mental health experts, the arrival of a new paradigm in breakthrough psychiatric drugs is long overdue.

Nonetheless, annual sales of antidepressant drugs keep surging higher every year. They currently total more than US$14bn, according to a study by Allied Market Research. Other estimates range as high as US$50bn worldwide.

In total, anxiety disorders and/or persistent depression affect up to 25% of the population in Europe, and a similar percentage of people in the USA. That is 250 million people combined the majority of which experience chronic anxiety. Yet they are commonly treated with anti-depressants due to a scarcity of effective medicine to treat people with frayed nerves.

As to whether psychedelics represent a prospectively better alternative, the public perception has always been that any therapeutic value they may have is outweighed by the dangers that they supposedly pose. However, 21st century observational studies conducted by healthcare professionals in controlled environments have consistently shown that participants have reported few or no negative side effects. Studies also show that psychedelics have low potential for abuse or dependence.

According to drug-harm experts, thepsilocybin in psychoactive mushrooms, mescaline in certain cactus, as well as the synthesised compounds in LSD and MDMA, rank among the least harmful drugs when factoring-in damage to health, drug dependency, economic harm, and the societal cost of crime.

Then there is a whole array of other anti-psychotic medications that might one day be replaced by psychedelics. As previously mentioned, the mental health market is worth an estimated $70bn a year globally, according to Bloomberg. Psychedelics stand to earn a sizeable share of this enormous market.

The market intelligence firm,Data Bridge Market Research,forecasts the psychedelic pharmaceuticals market could grow to almost $7bn by 2027 from almost a standing start. Meanwhile, a prominent Canadian investment bank, Canaccord Genuity, estimates that this nascent industry could eventually be worth $100bn.

Not surprisingly, Big Pharma is already beginning to get serious about this new frontier of medical science. After all, the industry has made massive profits from the sale of SSRIs while also becoming increasingly sensitive to the dangerous drawbacks of these controversial drugs.

Hence, an opportunity to help launch a new generation of more effective, yet less problematic mental health drugs must seem very appealing. Which is why Big Pharma will be keenly watching the progress of these biotech innovators in psychedelic medicine with a view to acquiring the best of the bunch for big-dollar sums.

Psychedelic drugs have at last shrugged off the stigma of the 1960s and are finally coming of age as a highly disruptive form of medical therapy. Besides a diversity of mental health ailments already mentioned, psychedelics are proving in observational trials to be especially effective at treating drug and alcohol addictions, too.

Additionally, they are even being developed to treat chronic pain and to help cigarette smokers quit for good. All of this means that up to two billion people may eventually benefit from access to these non-addictive, non-toxic, new drugs.

In summary, XPhyto has entered into two psychedelic agreements: first, for the development of industrial scale biotechnology processes for the production of psilocybin, and second, for research and development related to multiple psychedelic compounds, including psilocybin, mescaline, LSD, MDMA, DMT, among others.

Continue reading here:

XPhyto Therapeutics diversifies into psychedelics with new labs - Health Europa

NEW YORK, March 24, 2021 /PRNewswire/ --The push for psychedelic medicine is surging across North America and around the world. Scientific evidence supports the life-changing impact this safe and natural alternative has in treating mental illness of all types. New research from a number of organizations, including Johns Hopkinsin Baltimore and Imperial Collegein London, which revealed that patients with depressive disorders had a clinically significant positive response to psilocybin-assisted therapy may represent a therapeutic breakthrough in treating multiple neurological disorders. As research expands, so does support for the revolutionary treatment, which has actually been around for centuries. As seen before, anecdotal opinions often trigger scientific research which then, with validation, drives growth in the industry as well investor interest. That's exactly what's occurring in the psychedelic therapeutics space, major upticks in both new companies entering the space as well as investors excited about the possibilities. Potential stakeholders in this game-changing new market are looking for companies that can weather the complex and expensive process of running clinical trials and bringing a drug to market. A leader in psychedelic therapeutic research and drug development, Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF)(Profile)has a strong clinical pipeline with phase 2 trials underway, holds ten provisional patents,and boasts a proven leadership and a time-tested tradition. Other companies vying for position in the psychedelics medicine space include COMPASS Pathways Plc (NASDAQ: CMPS), Mind Medicine Inc (OTCQB: MMEDF) (NEO: MMED), Numinus Wellness Inc. (OTCPK: LKYSF) (NEO: NUMI) (TSX.V: NUMI) and Field Trip Health Ltd.(OTCQX: FTRPF) (CSE: FTRP). Each of these companies is focused on providing better treatments for the millions suffering from mental health issues.

Click hereto view the custom infographic of theCybin editorial.

The Psychedelic Answers

More than 700 million people worldwide struggle with some form of mental illness, be it depression, addiction or post-traumatic stress disorder and the people counted are just those who seek help. The actual number is likely much higher, given the high frequency of nondiagnosis as well as stigmas and lack of effective treatments. One in four people will face a mental or neurological disorder at some point in their lives, yet "current treatments and the dominant model of mental health care do not adequately address the complex challenges of mental illness, which accounts for roughly one-third of adult disability globally."

More and more people are looking outside conventional protocols for solutions, and they're finding those solutions in the world of psychedelic medicine, specifically psilocybins. Psilocybins are a hallucinogenic substance found in certain types of mushroom, dubbed magic mushrooms, and used for centuries by indigenous cultures for religious, spiritual and health-related purposes. As is often the case, the modern world is learning from the ancient as mounting evidence points to these prolific fungi as a source for long-sought-for help in mental health and neurological disorders.

A Legacy of Success

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF)is intent on becoming the leader in this exciting breakthrough for mental well-being. The company is at the forefront of the revolution in mental health therapeutics and is developing a new class of psychedelic medicines and treatment protocols. Driving its commitment to excellence is the company's impressive leadership team of experienced professionals with a combined 80-plus years in the pharmaceutical industry.

CEO Doug Drysdale has three decades in the health-care sector, successfully building and turning around three pharmaceutical companies, and co-founder Eric So has raised hundreds of millions for various companies, directing value creation and strategic exits. Cybin's executive team has the experience and critical insights to navigate through the complexities the promising psychedelics industry offers.

Staffed with luminaries, the company's scientific team,helped develop widely used drugs such as Allegra, Sabril, Anzemet and Vaniqa, and is the only scientific team to have successfully commercialized a psychedelic drug to date.In addition, the team has facilitated more than $2 billion in pharmaceutical sales alongside being collectively involved in 37 exits across the biotech sector and various other verticals. Cybin's leadership team has a rich legacy of success and has the proven ability to both guide the company and maximize opportunity.

Tested, Proven Fundraising Ability

The importance of being well funded can't be overlooked and is especially important for research and drug development. Cybin and its leadership team have demonstrated ability to raise funds for key, strategic steps necessary for success. Most recently, Cybin raised C$45 million in the largest go-public capital raise in the Canadian psychedelic sector and a total of C$88 million across Seed, Series-A and Series-B financing rounds.

Part of that capital was used in the company's strategic acquisition of Adelia Therapeutics Inc., whose novel psychedelic molecules allowed Cybin to diversity its portfolio and provided access to multiple future indications. The acquisition also resulted in Cybin obtaining a range of technologies related to novel therapeutic delivery methods and therapeutic regimens, along with six patent applications. The acquisition also brought with it an expanding library of psychedelic derivative drug development candidates, with the first lead compounds expected to enter clinical studies this year.

A Three-Pillar Pipeline

Cybin is committed to a strong, well-established IP portfolioand clinical pipeline, as indicated by the Adelia acquisition. The company leads the industry in therapeutic development programs and innovative drug delivery systems using a three-pillar strategy with its novel drug-discovery platform, optimal novel and proprietary drug-delivery systems, and an innovative treatment regimen.

The company's IP model is diverse, covering chemically synthesized molecules, delivery mechanisms, screeners, protocols and new drug formulations alongside a merger and acquisition strategy focused on acquiring proprietary technologies and novel compounds and molecules. In addition, Cybin holds worldwide exclusive rights to sublingual film delivery technology from Intelgenx for the delivery of psilocybin and other psychedelic molecules.

In addition, the company has key partnerships in place. Cybin recently partnered with neurotech pioneer Kernelto leverage its Kernel Flow, an innovative technology designed to detect hemodynamic changes in the brain that pulses light through the skull and into the bloodstream to measure how much oxygen the blood is carrying at any given time. Cybin anticipates that the quantitative measurements enabled by Flow may improve the development, delivery and scaling of its psychedelic therapeutics.

"Access to Kernel's innovative Flow technology adds another exciting dimension to the investigative work that Cybin is doing to develop breakthrough treatments for mental health disorders such as depression and addiction," said CEO Doug Drysdale. "Currently, clinical investigators rely on limited subjective information from patients. The ability to collect quantitative data from our sponsored drug development programs is potentially game-changing in terms of our ability to measure where psychedelics work in the brain in real time, and how we ultimately design our future therapeutics. . . . This new cornerstone component of our sponsored clinical programs follows a record-setting capital raise, listing on the NEO Exchange and the acquisition of Adelia Therapeutics Inc., which added significant scientific capabilities, novel molecules, delivery mechanisms and intellectual property."

Just this week Cybin announced that it had signed a drug-development agreement with Catalent Inc., the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. Cybin will be applying Catalent's proprietary Zydis(R)orally disintegrating tablet technology for the delivery of its novel deuterated tryptamine, or CYB003, a potential therapy for treatment-resistant psychiatric disorders.

"We are excited to partner with the team at Catalent with the aim of developing fast-acting, shorter-duration formulations of CYB003, recently acquired as part of our acquisition of Adelia Therapeutics," Drysdale said. "Our focus on reducing the need for health system resources, such as in-clinic therapist time, is an important part of our goal to create scalable, more accessible treatments for mental health disorders."

There's little doubt about the lack of effective treatments for mental health and neurological disorders. Scientific research is revealing a new, more effective approaches to address the massive unmet medical need. Leaders in this new frontier of medicine will likely be both appreciated by patients and rewarded by the markets.

Making a Profit and a Difference

Cybin isn't alone in the quest to make a difference in the mental health space. Savvy companies see an opportunity in psychedelic therapeutics and are jostling for position in an industry destined to make a mark.

COMPASS Pathways Plc (NASDAQ: CMPS) intends to accelerate patient access to evidence-based innovation in mental health. "We focus our efforts on those who are not helped by current treatments," states the company, which is developing its COMP360 psilocybin therapy designed to offer relief for the millions of people who suffer with treatment-resistant depression (TRD). The company is pioneering the development of this therapy, in which its proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support.

Mind Medicine Inc (OTC: MMEDF) (NEO: MMED)is a psychedelic medicine biotech company that discovers, develops and deploys psychedelic-inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC.

MMED is also actively pursuing the development of LSD-assisted therapies through its Project Lucy, including a Phase2btrial for anxiety disorders planned to be conducted fully through the FDA pathway.

Numinus Wellness Inc. (OTC: LKYSF) (NEO: NUMI) (TSX.V: NUMI)supports access to psychedelic-assisted psychotherapy through ketamine-assisted psychotherapy and special access and compassionate trials. Numinus partners with practitioners in providing clients with access to psychedelic-assisted psychotherapy, and through its recent acquisition of Mindspace, a Quebec-based psychedelic programming leader, Numinus now supports practitioners across three clinic locations.

Field Trip Health Ltd.(OTCQX: FTRPF) (CNX: FTRP), a global leader in the development and delivery of psychedelic therapies, recently partneredwith WHOOP, a human performance company, to measure the biometric effects of Field Trip's psychedelic therapies. Field Trip is opening Field Trip Health centers across North America and Europe for the delivery of psychedelic therapies, which have demonstrated significant efficacy in treating mental health conditions such as depression, anxiety and PTSD.

Surging interest in psychedelic therapeutics has sparked rising involvement from savvy companies interested in making both a profit and a difference as well as investors looking for the next space to strategically make a move. Companies such as Cybin that offer the science, the leadership and the expertise needed to succeed have a good chance of making a real difference in the nascent industry.

For more information about Cybin, please visitCybin Inc.

About NetworkNewsWire

NetworkNewsWire("NNW") is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork("IBN"), that provides: (1) access to a network of wire solutions via NetworkWireto reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text "STOCKS" to 77948 (U.S. Mobile Phones Only)

For more information, please visit: https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:http://NNW.fm/Disclaimer

NetworkNewsWire is part of theInvestorBrandNetwork

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with NNW or any company mentioned herein. The commentary, views and opinions expressed in this release by NNW are solely those of NNW and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW and FNM for any investment decisions by their readers or subscribers. NNW and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment.

NNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW and FNM undertake no obligation to update such statements.

Corporate Communications Contact:

NetworkNewsWire (NNW)New York, New Yorkwww.NetworkNewsWire.com212.418.1217 Office[emailprotected]

Media Contact:FN Media Group, LLC[emailprotected]+1-(954)345-0611

SOURCE NetworkNewsWire

Read more here:

Science Drives Surging Interest in Psychedelic Therapeutics - PRNewswire

MIAMI, March 22, 2021 (GLOBE NEWSWIRE) -- 20/20 Global, Inc. dba Mycotopia Therapies, (OTC Pink: TWGL) (the Company), a company focused on psychedelic therapies, announced today it has formed PsyBioMed Australia and entered into a letter of intent to jointly conduct clinical trials in Australia using psychedelics to treat mental illness. PsyBioMed Australia will be a joint venture between Mycotopia Therapies and Melbourne, Victoria based psychedelic research and development company Natural MedTech. It is expected that PsyBioMed-Australia will build and develop a R&D laboratory and a manufacturing facility in Victoria using technology to be provided by Ehave, Inc. (OTC: EHVVF) to capture and analyze data.

According to data released by the Australian Institute of Health and Welfare 4.3 million Australia patients (17.1% of the Australian population) received a mental health-related prescription in 201819 with 70.9% (27.6 million) of those being antidepressant medications. With anti-depressant usage on the rise over the years and currently with over 3 million Australians on anti-depressants, there are hundreds of thousands of patients that meet the criteria for psychedelic assisted therapies in Australia.PsyBioMed aims to close the loop in the broken supply chain and produce Current Good Manufacturing Practice (cGMP) psychedelics in Australia, while researching various other molecules that can be translated into clinical practice.

Medicallysupervised, legal access to evidence-based Psychedelic-Assisted Psychotherapy is becoming increasingly available through clinical trials for multiple conditions throughout Australia. The Australian government through the Medical Research Future Fund (MRFF) has allocated $15 million to fund clinical research into Ketamine, Psilocybin and MDMA Assisted therapies in order to fully ascertain the safety and impacts of these kinds of drugs compared to existing drugs. This research by the Australian government into whether psychedelic drugs are more effective than existing treatments sets the stage for large-scale clinical trials.

PsyBioMed-Australia intends to obtain licences and permits to legally possess, supply, sell and manufacture Schedule 8 & 9 Drugs (Schedule 9 is equivalent to Americas Schedule 1) in order to produce cGMP psychedelics in Australia. PsyBioMed-Australias Victoria, Australia based facilities will have the capabilities to undertake genetic approaches and apply both mycology and synthetic biology techniques in both R&D and full GMP environments. PsyBioMed-Australia plans to produce medicine at a standard for human consumption, develop IP and supply upcoming clinical trials, as well as health institutions and physicians when appropriate.

The partnership with Natural MedTech provides PsyBioMed access to various forms of intellectual property, an expert team of local scientists, medical professionals, university, and industry partners that are pioneers in their respective fields and are passionate about developing novel therapies for the unmet need that is mental ill health.

Mycotopia Therapies, through its relationship with Ehave, provides PsyBioMed with IP access to digital therapeutic blockchain technology that allows for the secure and compliant capture of in-depth data sets. This data capture will be used to clinically validate some of these more experimental forms of therapy including psychedelic and ketamine treatments whilst allowing patients to own their own data and do what they want with it.

This type of data capture will allow for effective N-of-1 type studies in alignment with the Royal Australian and New Zealands College of Psychiatrist Clinical Memorandum Therapeutic use of psychedelic substances.

Ben Kaplan, CEO of Mycotopia Therapies, said, It is estimated 4 million Australians experience a mental health disorder every year, and almost half of all Australians will be affected at some point in their lifetime. PsyBioMed-Australia will provide the opportunity to boost local research into potentially lifesaving therapies while creating a supply chain for their distribution.

Dr. Manideep Gopishetty, CMO of Mycotopia Therapies, said, Increasingresearch evidencesuggests MDMA, commonly known as ecstasy, could be an effective adjunct to psychotherapy for people with post-traumatic stress disorder (PTSD). Meanwhile, clinical trials of psilocybin, the psychoactive component of magic mushrooms, show it could assist psychotherapy in the treatment of anxiety, depression, addiction and other mood-based disorders all of which aligns with our research and drug development roadmap. We strongly believe Australia would be a pivotal point for global distribution of psychedelics and special access program of Australia designed for medical consumption of psychedelics in chronic mental health conditions is a perfect model created by the Australian government to enable this drug delivery process very seamlessly by having all regulatory protocols in place.

Mark Hestermann, CEO of Natural MedTech, said, Australia is often considered a lucky country, but we have one of the highest rates of mental ill health globally. Something is wrong. I believe that people deserve better than to live with symptom management when there are more promising treatment options at our doorstep. Our mission is to break the symptom management cycle thats all too prevalent in mental healthcare and offer alternative and meaningful solutions for people who are suffering.

Dr Jamie Rickcord, Founder of Ananda Clinics, said, In order for us to safely introduce psychedelic assisted therapy into Australian practice, having access to GMP grade psychedelic medicines is an urgent need. Recent announcements from the Australian government of $15 million to fund research into psychedelic therapies highlights the need for these medicines to be available. Australia will soon be on the leading edge of the renaissance and as we build data and experience in psychedelic medicine it will be another leap to have access to locally produced medicines. The combination of local research and production will allow suffering Australian's to access these therapies safely and in timely manner. This partnership is the innovation and forward thinking required at this crucial stage in the introduction of psychedelic medicine in Australia.

About Mycotopia Therapies

Mycotopia Therapies focuses on helping you heal and reclaim your life. Your journey of healing is an understanding of the causes and works to mental wellness through psychedelic enhanced psychotherapy, integrated with a professional team of mental wellness practitioners and cutting-edge technology. Psychedelic therapy is a holistic and spiritual approach providing healing and has shown successful treatment for many years. Additional information on Mycotopia Therapies can be found on the Companys website at: https://www.mycotopiatherapies.com.

About Natural MedTech

Natural MedTech is a biotech company driven by a passion to bring optimum health and wellness by translating modern advancements into meaningful action. Natural MedTech conducts drug development, engages and supports clinical trials with the goal of advancing clinical application of psychedelics and other scheduled compounds of therapeutic relevance. Our initial focus is to manufacture GMP psilocybin in Australia and provide innovative solutions to address current public health challenges of today.

We are focused on psychedelic advancements, but we understand that psychedelics arent the whole picture. Natural MedTech promotes its Seven (7) pillars of health, which are in Personalized Nutrition, Exercise, Personalized Medicine, Mindfulness Meditation, Breathwork, Sleep, and Psychedelic Medicines. https://www.naturalmedtech.com

Forward-Looking Statement Disclaimer

This press release contains forward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995. Such statements may be preceded by the wordsintends, may, will, plans, expects, anticipates, projects, predicts, estimates, aims, believes, hopes, potential or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Companys research, manufacturing and other development efforts; (ii) the Companys ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Companys products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Companys industry and introduction of competing products; (vi) the Companys ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "RiskFactors" in 20/20 Global, Inc.s RegistrationStatement on Form F-1 filed with the Securities and Exchange Commission (SEC) onSeptember 24, 2015, as amended, which is available on the SEC's website, http://www.sec.gov.

Contact for 20/20 Global and Ehave

Media Inquiries: Gabe Rodriguez

Email: Gabe@Ehave.com

Investor Relations:

Email: Ir@Ehave.com

Phone: (623) 261-9046

Visit link:

Psychedelic Joint Venture Between Mycotopia Therapies and Natural MedTech Brings Research and Drug Development to Test Active Ingredient In...

DUBLIN--(BUSINESS WIRE)--The "Global Psychedelic Drugs Market: Size & Forecast with Impact Analysis of COVID-19 (2021-2025)" report has been added to ResearchAndMarkets.com's offering.

"Global Psychedelic Drugs Market: Size & Forecast with Impact Analysis of COVID-19 (2021-2025)", provides an in depth analysis of the global psychedelic drugs market by value, by indication, etc. The report also provides a detailed analysis of the COVID-19 impact on the psychedelic drugs market.

Recently, the use of psychedelics is evolving for the treatment of a variety of mental illnesses, including anxiety, depression, post-traumatic stress disorder, etc.

Some psychedelic drugs are extracted from plants or mushrooms, and some are synthetic (human-made). These drugs are now considered effective for patients with treatment-resistant depression, as they are fast-acting and long-lasting.

The most common psychedelic substances include: Ketamine, Psilocybin, Ibogaine, LSD, Dimethyltryptamine (DMT), or MDMA. The majority of psychedelic drugs under development are targeting mental and/or behavioral health indications. This is an area with significant unmet need.

The psychedelic drugs market can be segmented on the basis of indication (ADHD, MDD, Bipolar, Migraine, Anxiety, Parkinson's Disease, OUD, Alzheimer's Disease, AUD, TUD, Eating Disorder, and Narcolepsy); and drug type (Lysergic Acid Diethylamide (LSD), Ketamine, Psilocybin, 3,4-MethylEnedioxyMethamphetamine (MDMA), Ibogaine, and Others).

The global psychedelic drugs market has increased significantly during the years 2018-2020 and projections are made that the market would rise in the next four years i.e. 2021-2025 tremendously. The psychedelic drugs market is expected to increase due to rising prevalence of depression and mental disorders, regulatory reforms, developments relating to psychedelics, changing perceptions, little severe side effects and cost effective, etc. Yet the market faces some challenges such as uncertainty around getting the FDA approval, early stage in lifecycle of the psychedelics industry, stigma associated with psychedelic drugs use, etc.

The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global psychedelic drugs market has also been forecasted for the period 2021-2025, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

The global psychedelic drugs market remains at a early stage in its life cycle, with most companies currently developing their go-to-market strategy. The market players of psychedelics are involved in the clinical trials of several psychedelic drugs to address mental health, which continues to present significant unmet need.

The key players of the psychedelic drugs market are COMPASS Pathways Plc, Mind Medicine (MindMed) Inc., Numinus Wellness Inc., and Johnson & Johnson are also profiled with their financial information and respective business strategies.

Key Topics Covered:

1. Executive Summary

2. Introduction

2.1 Psychedelic Drugs: An Overview

2.1.1 History of Psychedelic Drugs

2.1.2 Pros and Cons of Psychedelic Drugs

2.1.3 Major Types of Psychedelic Drugs

2.1.4 Potential Treatment Indications for Psychedelic Molecules

2.1.5 Psychedelic Classification

2.2 Psychedelic Drugs Segmentation: An Overview

2.2.1 Psychedelic Drugs Segmentation by Indication

2.2.2 Psychedelic Drugs Segmentation by Drug Type

3. Global Market Analysis

3.1 Global Psychedelic Drugs Market: An Analysis

3.1.1 Global Psychedelic Drugs Market by Value

3.1.2 Global Psychedelic Drugs Market by Indication (ADHD, MDD, Bipolar, Migraine, Anxiety, Parkinson's Disease, OUD, Alzheimer's Disease, AUD, TUD, Eating Disorder and Narcolepsy)

3.2 Global Psychedelic Drugs Market: Indication Analysis

3.2.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Psychedelic Drugs Market by Value

3.2.2 Global Major Depressive Disorder (MDD) Psychedelic Drugs Market by Value

3.2.3 Global Bipolar Disorder Psychedelic Drugs Market by Value

3.2.4 Global Migraine Psychedelic Drugs Market by Value

3.2.5 Global Anxiety Psychedelic Drugs Market by Value

3.2.6 Global Parkinson's Disease Psychedelic Drugs Market by Value

3.2.7 Global Opioid Use Disorder (OUD) Psychedelic Drugs Market by Value

3.2.8 Global Alzheimer's Disease Psychedelic Drugs Market by Value

3.2.9 Global Alcohol Use Disorder (AUD) Psychedelic Drugs Market by Value

3.2.10 Global Tobacco Use Disorder (TUD) Psychedelic Drugs Market by Value

3.2.11 Global Eating Disorder Psychedelic Drugs Market by Value

3.2.12 Global Narcolepsy Psychedelic Drugs Market by Value

4. Impact of COVID-19

4.1 Impact of COVID-19

4.1.1 Impact of COVID-19 on Healthcare Sector

4.1.2 Impact of COVID-19 on Psychedelic Drugs Industry

5. Market Dynamics

5.1 Growth Driver

5.1.1 Rising Prevalence of Depression and Mental Disorders

5.1.2 Regulatory Reforms

5.1.3 Developments Relating to Psychedelics

5.1.4 Changing Perceptions

5.1.5 Little Severe Side Effects and Cost effective

5.2 Challenges

5.2.1 Uncertainty around Getting the FDA Approval

5.2.2 Early Stage in Lifecycle of the Psychedelics Industry

5.2.3 Stigma Associated with Psychedelic Drugs Use

5.3 Market Trends

5.3.1 Rising Approval for Additional Psychedelic Drugs

5.3.2 Growing Popularity of Psilocybin

5.3.3 Rising Number of Potential Candidates for Breakthrough Therapy Designation (BTD)

5.3.4 Surging popularity of Micro-dosing in Psychedelics

5.3.5 Emergence of Psychedelic-assisted Psychotherapy (PAP)

5.3.6 Increasing Potential Treatment Indications for Psychedelic Drugs

6. Competitive Landscape

6.1 Global Psychedelic Drugs Market Players by Drug TAM

6.2 Global Psychedelic Drugs Market Players by Psychedelic Related Businesses

6.3 Global Psychedelic Drugs Market Players by Psychedelic-related Clinical Trials

6.4 Global Psychedelic Drugs Market Players by Breakthrough Therapy Designations (BTD) for Psychedelic Substances

7. Company Profiles

7.1 COMPASS Pathways Plc

7.2 Mind Medicine (MindMed) Inc.

7.3 Numinus Wellness Inc.

7.4 Johnson & Johnson

For more information about this report visit https://www.researchandmarkets.com/r/eke13d

Original post:

Global Psychedelic Drugs Market 2021-2025: Rising Number of Potential Candidates for Breakthrough Therapy Designation (BTD) - ResearchAndMarkets.com -...

It will come as a surprise to some that a clinical trial at a major metropolitan hospital is testing a treatment for alcohol use disorder that involves psilocybin, better known as the "magic mushroom."

But to those who have been following the expanding research into psychedelic-assisted therapy--for conditions ranging from addiction to depression and PTSD--what's new is not the psilocybin, but combining it with video.

"This is a novel approach," said Daniel Kelly, MD and neurosurgeon who is director of the Pacific Neuroscience Institute, part of St. John's Medical Center in Santa Monica, conducting the trial.

Local news from across Southern California

"Truly groundbreaking" and "historic" are the words used by filmmaker Louie Schwartzberg, who created the video.

The hypothesis is that appropriate video can enhance or "prime" the psilocybin-induced "mystical experience," which previous research has indicated can be effective for patients who desire to resolve psychological challenges.

There is need for new approaches, given the inconsistent results of traditional addiction treatments.

Though perhaps best remembered in popular culture as a recreational accessory of the 60s counter-culture, recognition of psilocybin's hallucinogenic powers dates back to ancient times.

"There's a long history of shamanistic cultures using these very successfully to manage these issues," said Dr. Kelly.

In the 1950s psychedelics, including psilocybin, became the subject of therapeutic research at Harvard University, among other established institutions.

But the excesses of the '60s put such research "into a deep freeze," as Dr. Kelly recounts the prologue, until just before the turn of the new century.

"There's a renaissance in psychedelic-assisted therapy that's been going on now for perhaps the last 20 years," said Dr. Kelly. "To me, as a neuroscientist, I think this is perhaps the most interesting thing going on in the neurosciences right now--because there's so much potential to help so many people in need."

During typical psychedelic therapy with psilocybin, the patient relaxes in a calm space, receives a dose of the active ingredient, and while monitored goes into a hallucinogenic state for several hours, a "mystical experience," or more simply, a trip. Patients are screened in advance for suitability and undergo "integration sessions" with a therapist, and afterward, there is follow-up.

Beyond the physiological fact that psilocybin triggers serotonin receptors, how it works is still not exactly clear. The prevailing sense is that this enables communication between different areas of the brain, bypassing and interruptingnormal thought patterns in the "default mode network," temporarily turning it off."This cross-referencing and cross-talk that occurs during the journey is thought to somehow allow people to come to these insights that they couldn't otherwise get as to whytheir behavior is so stuck in this rut," Dr. Kelly said.

But in not every case was a standard dose found to produce an adequate "mystical experience" to bring about change.

A considerable portion of the research in recent years has taken place at Johns Hopkins University Medical Center in Baltimore.

Filmmaker Schwartzberg obtained permission to film some of that therapy for his 2019 film Fantastic Fungi, devoted to exploring the mushroom, its place in the world and its powers.

"I think it shaped my life," Schwartzberg said of his own first experience with psilocybin while in college. "it's like the deepest meditative experience."

He became a believer in the healing power of nature, and documenting it became a specialty of his filmmaking.

During his filming at Johns Hopkins, Schwartzberg recalls, seeing patients wearing eye-shades, it occurred to him that nature visuals can be brought into a clinical setting.

"Nature is a healing modality. So I want to be able to bring that into healthcare," said Schwartzberg.

His work has been used at UC San Diego Health's Jacobs Medical Center, where patients can choose the visual ambiance of their room, and also at the University of Texas BrainHealth Center in Dallas.

His opportunity to test his belief that nature visuals can further psychedelic therapy came after he and Dr. Kelly met at a consciousness forum in Madison, Wisconsin.

Under Dr. Kelly, a co-founder of the Pacific Neurosciences Institute, it launched a program called Treatment & Research in Psychedelics, with the conveniently appropriate acronym, "TRIP," under the direction of addiction specialist Keith Heinzerling, MD. He is also the principal investigator of the new trial, the Institute's first, formally known as the "Visual Healing" study.

"Psilocybin-assisted therapy shows promise for treating alcohol use disorder,but early studies suggest that patients with alcohol problems may be less likelyto achieve a mystical experience with a standard psilocybin dose," stated Dr. Heinzerling.

The goal of achieving the effect without resorting to a larger dose is where the film Schwartzberg created for the trial comes in, with a visual theme of recurring patterns in nature, emphasized with time lapse, slow motion, and other visual techniques.

"Bending your human perception, by taking the patient on a journey through time and scale," is how Schwartzberg describes it. "And what that does is it opens you up, just as the psilocybin opens you up."

There will also be a control group that does not get "primed" with the video.

"Our hypothesis is that these patients who get the nature-themed video will have a higher likelihood of trying to deal with their drinking and reduce their intake or stop drinking altogether," said Dr. Kelly.

He emphasized that a team of professionals work to create the appropriate "set and setting," for every patient; that this is not something to be taken lightly.

Unlike opiates, tobacco, and often alcohol, psilocybin is not considered addictive. It is a controlled substance, schedule 1, the same schedule where you find heroin. But in 2018, the FDA issued a breakthrough therapy designation to several firms developing psilocybin treatments. Under some interpretations, psilocybin could also be prescribed for terminally ill patients under the Right to Try Act of 2018. Several cities have voted to decriminalize, and a bill introduced last month in California's legislature, SB 519, would recognize its therapeutic potential, and legalize possession, use and sharing, though not sale.

Though they are very different drugs, Schwartzberg envisions psilocybin following the path of cannabis to legalized medicinal use. And he's not alone.

"I think this psychedelic renaissance is transforming behavioral healthcare," Dr. Kelly said. "It's long overdue."

Go here to read the rest:

Adding a Cinematic Twist to Magic Mushrooms' as Medical Treatment - NBC Southern California